Global Antidiabetic SGLT-2 Inhibitor Market Research Report 2021

Global Antidiabetic SGLT-2 Inhibitor Market Research Report 2021

Table of Contents
1 Antidiabetic SGLT-2 Inhibitor Market Overview
1.1 Product Overview and Scope of Antidiabetic SGLT-2 Inhibitor
1.2 Antidiabetic SGLT-2 Inhibitor Segment by Type
1.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Canagliflozin
1.2.3 Empagliflozin
1.2.4 Dapagliflozin
1.2.5 Other
1.3 Antidiabetic SGLT-2 Inhibitor Segment by Application
1.3.1 Antidiabetic SGLT-2 Inhibitor Sales Comparison by Application: (2021-2027)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Global Antidiabetic SGLT-2 Inhibitor Market Size Estimates and Forecasts
1.4.1 Global Antidiabetic SGLT-2 Inhibitor Revenue 2016-2027
1.4.2 Global Antidiabetic SGLT-2 Inhibitor Sales 2016-2027
1.4.3 Antidiabetic SGLT-2 Inhibitor Market Size by Region: 2016 Versus 2021 Versus 2027
2 Antidiabetic SGLT-2 Inhibitor Market Competition by Manufacturers
2.1 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Manufacturers (2016-2021)
2.2 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Antidiabetic SGLT-2 Inhibitor Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Antidiabetic SGLT-2 Inhibitor Manufacturing Sites, Area Served, Product Type
2.5 Antidiabetic SGLT-2 Inhibitor Market Competitive Situation and Trends
2.5.1 Antidiabetic SGLT-2 Inhibitor Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Antidiabetic SGLT-2 Inhibitor Players Market Share by Revenue
2.5.3 Global Antidiabetic SGLT-2 Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antidiabetic SGLT-2 Inhibitor Retrospective Market Scenario by Region
3.1 Global Antidiabetic SGLT-2 Inhibitor Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Antidiabetic SGLT-2 Inhibitor Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
3.3.1 North America Antidiabetic SGLT-2 Inhibitor Sales by Country
3.3.2 North America Antidiabetic SGLT-2 Inhibitor Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
3.4.1 Europe Antidiabetic SGLT-2 Inhibitor Sales by Country
3.4.2 Europe Antidiabetic SGLT-2 Inhibitor Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Region
3.5.1 Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Region
3.5.2 Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
3.6.1 Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country
3.6.2 Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
3.7.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country
3.7.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Antidiabetic SGLT-2 Inhibitor Historic Market Analysis by Type
4.1 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2016-2021)
4.2 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2016-2021)
4.3 Global Antidiabetic SGLT-2 Inhibitor Price by Type (2016-2021)
5 Global Antidiabetic SGLT-2 Inhibitor Historic Market Analysis by Application
5.1 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2016-2021)
5.2 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2016-2021)
5.3 Global Antidiabetic SGLT-2 Inhibitor Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Pfizer Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2016-2021)
6.2.4 AstraZeneca Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Johnson & Johnson
6.3.1 Johnson & Johnson Corporation Information
6.3.2 Johnson & Johnson Description and Business Overview
6.3.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Johnson & Johnson Product Portfolio
6.3.5 Johnson & Johnson Recent Developments/Updates
6.4 GlaxoSmithKline
6.4.1 GlaxoSmithKline Corporation Information
6.4.2 GlaxoSmithKline Description and Business Overview
6.4.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2016-2021)
6.4.4 GlaxoSmithKline Product Portfolio
6.4.5 GlaxoSmithKline Recent Developments/Updates
6.5 Merck & Co
6.5.1 Merck & Co Corporation Information
6.5.2 Merck & Co Description and Business Overview
6.5.3 Merck & Co Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Merck & Co Product Portfolio
6.5.5 Merck & Co Recent Developments/Updates
6.6 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Eli Lilly Product Portfolio
6.6.5 Eli Lilly Recent Developments/Updates
6.7 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Sanofi Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 Takeda Pharmaceuticals
6.8.1 Takeda Pharmaceuticals Corporation Information
6.8.2 Takeda Pharmaceuticals Description and Business Overview
6.8.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Takeda Pharmaceuticals Product Portfolio
6.8.5 Takeda Pharmaceuticals Recent Developments/Updates
6.9 Novo Nordisk
6.9.1 Novo Nordisk Corporation Information
6.9.2 Novo Nordisk Description and Business Overview
6.9.3 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Novo Nordisk Product Portfolio
6.9.5 Novo Nordisk Recent Developments/Updates
6.10 Servier Laboratories
6.10.1 Servier Laboratories Corporation Information
6.10.2 Servier Laboratories Description and Business Overview
6.10.3 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Servier Laboratories Product Portfolio
6.10.5 Servier Laboratories Recent Developments/Updates
6.11 Boehringer Ingelheim
6.11.1 Boehringer Ingelheim Corporation Information
6.11.2 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Description and Business Overview
6.11.3 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Boehringer Ingelheim Product Portfolio
6.11.5 Boehringer Ingelheim Recent Developments/Updates
6.12 Bristol-Myers Squibb
6.12.1 Bristol-Myers Squibb Corporation Information
6.12.2 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Description and Business Overview
6.12.3 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Bristol-Myers Squibb Product Portfolio
6.12.5 Bristol-Myers Squibb Recent Developments/Updates
7 Antidiabetic SGLT-2 Inhibitor Manufacturing Cost Analysis
7.1 Antidiabetic SGLT-2 Inhibitor Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Antidiabetic SGLT-2 Inhibitor
7.4 Antidiabetic SGLT-2 Inhibitor Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Antidiabetic SGLT-2 Inhibitor Distributors List
8.3 Antidiabetic SGLT-2 Inhibitor Customers
9 Antidiabetic SGLT-2 Inhibitor Market Dynamics
9.1 Antidiabetic SGLT-2 Inhibitor Industry Trends
9.2 Antidiabetic SGLT-2 Inhibitor Growth Drivers
9.3 Antidiabetic SGLT-2 Inhibitor Market Challenges
9.4 Antidiabetic SGLT-2 Inhibitor Market Restraints
10 Global Market Forecast
10.1 Antidiabetic SGLT-2 Inhibitor Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Antidiabetic SGLT-2 Inhibitor by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Antidiabetic SGLT-2 Inhibitor by Type (2022-2027)
10.2 Antidiabetic SGLT-2 Inhibitor Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Antidiabetic SGLT-2 Inhibitor by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Antidiabetic SGLT-2 Inhibitor by Application (2022-2027)
10.3 Antidiabetic SGLT-2 Inhibitor Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Antidiabetic SGLT-2 Inhibitor by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Antidiabetic SGLT-2 Inhibitor by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) Comparison by Application (2021-2027)
Table 3. Global Antidiabetic SGLT-2 Inhibitor Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Antidiabetic SGLT-2 Inhibitor Covered in This Study
Table 5. Global Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) of Key Manufacturers (2016-2021)
Table 6. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Manufacturers (2016-2021)
Table 7. Global Antidiabetic SGLT-2 Inhibitor Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Antidiabetic SGLT-2 Inhibitor Average Price (USD/Pcs) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Antidiabetic SGLT-2 Inhibitor Manufacturing Sites and Area Served
Table 11. Manufacturers Antidiabetic SGLT-2 Inhibitor Product Type
Table 12. Global Antidiabetic SGLT-2 Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Antidiabetic SGLT-2 Inhibitor by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antidiabetic SGLT-2 Inhibitor as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2016-2021) & (K Pcs)
Table 16. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2016-2021)
Table 17. Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2016-2021) & (K Pcs)
Table 19. North America Antidiabetic SGLT-2 Inhibitor Sales Market Share by Country (2016-2021)
Table 20. North America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Country (2016-2021)
Table 22. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2016-2021) & (K Pcs)
Table 23. Europe Antidiabetic SGLT-2 Inhibitor Sales Market Share by Country (2016-2021)
Table 24. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Region (2016-2021) & (K Pcs)
Table 27. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2016-2021)
Table 30. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country (2016-2021) & (K Pcs)
Table 31. Latin America Antidiabetic SGLT-2 Inhibitor Sales Market Share by Country (2016-2021)
Table 32. Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2016-2021) & (K Pcs)
Table 35. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Country (2016-2021)
Table 38. Global Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) by Type (2016-2021)
Table 39. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2016-2021)
Table 40. Global Antidiabetic SGLT-2 Inhibitor Revenue (Million US$) by Type (2016-2021)
Table 41. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Type (2016-2021)
Table 42. Global Antidiabetic SGLT-2 Inhibitor Price (USD/Pcs) by Type (2016-2021)
Table 43. Global Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) by Application (2016-2021)
Table 44. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2016-2021)
Table 45. Global Antidiabetic SGLT-2 Inhibitor Revenue (Million US$) by Application (2016-2021)
Table 46. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Application (2016-2021)
Table 47. Global Antidiabetic SGLT-2 Inhibitor Price (USD/Pcs) by Application (2016-2021)
Table 48. Pfizer Corporation Information
Table 49. Pfizer Description and Business Overview
Table 50. Pfizer Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 51. Pfizer Antidiabetic SGLT-2 Inhibitor Product
Table 52. Pfizer Recent Developments/Updates
Table 53. AstraZeneca Corporation Information
Table 54. AstraZeneca Description and Business Overview
Table 55. AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 56. AstraZeneca Antidiabetic SGLT-2 Inhibitor Product
Table 57. AstraZeneca Recent Developments/Updates
Table 58. Johnson & Johnson Corporation Information
Table 59. Johnson & Johnson Description and Business Overview
Table 60. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 61. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product
Table 62. Johnson & Johnson Recent Developments/Updates
Table 63. GlaxoSmithKline Corporation Information
Table 64. GlaxoSmithKline Description and Business Overview
Table 65. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 66. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product
Table 67. GlaxoSmithKline Recent Developments/Updates
Table 68. Merck & Co Corporation Information
Table 69. Merck & Co Description and Business Overview
Table 70. Merck & Co Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 71. Merck & Co Antidiabetic SGLT-2 Inhibitor Product
Table 72. Merck & Co Recent Developments/Updates
Table 73. Eli Lilly Corporation Information
Table 74. Eli Lilly Description and Business Overview
Table 75. Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 76. Eli Lilly Antidiabetic SGLT-2 Inhibitor Product
Table 77. Eli Lilly Recent Developments/Updates
Table 78. Sanofi Corporation Information
Table 79. Sanofi Description and Business Overview
Table 80. Sanofi Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 81. Sanofi Antidiabetic SGLT-2 Inhibitor Product
Table 82. Sanofi Recent Developments/Updates
Table 83. Takeda Pharmaceuticals Corporation Information
Table 84. Takeda Pharmaceuticals Description and Business Overview
Table 85. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 86. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product
Table 87. Takeda Pharmaceuticals Recent Developments/Updates
Table 88. Novo Nordisk Corporation Information
Table 89. Novo Nordisk Description and Business Overview
Table 90. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 91. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product
Table 92. Novo Nordisk Recent Developments/Updates
Table 93. Servier Laboratories Corporation Information
Table 94. Servier Laboratories Description and Business Overview
Table 95. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 96. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product
Table 97. Servier Laboratories Recent Developments/Updates
Table 98. Boehringer Ingelheim Corporation Information
Table 99. Boehringer Ingelheim Description and Business Overview
Table 100. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 101. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product
Table 102. Boehringer Ingelheim Recent Developments/Updates
Table 103. Bristol-Myers Squibb Corporation Information
Table 104. Bristol-Myers Squibb Description and Business Overview
Table 105. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 106. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product
Table 107. Bristol-Myers Squibb Recent Developments/Updates
Table 108. Production Base and Market Concentration Rate of Raw Material
Table 109. Key Suppliers of Raw Materials
Table 110. Antidiabetic SGLT-2 Inhibitor Distributors List
Table 111. Antidiabetic SGLT-2 Inhibitor Customers List
Table 112. Antidiabetic SGLT-2 Inhibitor Market Trends
Table 113. Antidiabetic SGLT-2 Inhibitor Growth Drivers
Table 114. Antidiabetic SGLT-2 Inhibitor Market Restraints
Table 115. Global Antidiabetic SGLT-2 Inhibitor Sales Forecast by Type (2022-2027) & (K Pcs)
Table 116. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share Forecast by Type (2022-2027)
Table 117. Global Antidiabetic SGLT-2 Inhibitor Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 118. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share Forecast by Type (2022-2027)
Table 119. Global Antidiabetic SGLT-2 Inhibitor Sales Forecast by Application (2022-2027) & (K Pcs)
Table 120. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share Forecast by Application (2022-2027)
Table 121. Global Antidiabetic SGLT-2 Inhibitor Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 122. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share Forecast by Application (2022-2027)
Table 123. Global Antidiabetic SGLT-2 Inhibitor Sales Forecast by Region (2022-2027) & (K Pcs)
Table 124. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share Forecast by Region (2022-2027)
Table 125. Global Antidiabetic SGLT-2 Inhibitor Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 126. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share Forecast by Region (2022-2027)
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Antidiabetic SGLT-2 Inhibitor
Figure 2. Global Antidiabetic SGLT-2 Inhibitor Market Share by Type in 2020 & 2027
Figure 3. Canagliflozin Product Picture
Figure 4. Empagliflozin Product Picture
Figure 5. Dapagliflozin Product Picture
Figure 6. Other Product Picture
Figure 7. Global Antidiabetic SGLT-2 Inhibitor Market Share by Application in 2020 & 2027
Figure 8. Hospitals
Figure 9. Clinics
Figure 10. Other
Figure 11. Global Antidiabetic SGLT-2 Inhibitor Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Antidiabetic SGLT-2 Inhibitor Market Size 2016-2027 (US$ Million)
Figure 13. Global Antidiabetic SGLT-2 Inhibitor Sales 2016-2027 (K Pcs)
Figure 14. Global Antidiabetic SGLT-2 Inhibitor Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 15. Antidiabetic SGLT-2 Inhibitor Sales Share by Manufacturers in 2020
Figure 16. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Manufacturers in 2020
Figure 17. The Global 5 and 10 Largest Antidiabetic SGLT-2 Inhibitor Players: Market Share by Revenue in 2020
Figure 18. Antidiabetic SGLT-2 Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 19. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2016-2021)
Figure 20. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region in 2020
Figure 21. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2016-2021)
Figure 22. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region in 2020
Figure 23. U.S. Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Canada Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Germany Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. France Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. U.K. Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Italy Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Russia Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. China Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Japan Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. South Korea Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. India Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Australia Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Taiwan Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Indonesia Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Thailand Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Malaysia Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Philippines Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Vietnam Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Mexico Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Brazil Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Argentina Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Turkey Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Saudi Arabia Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. U.A.E Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Sales Market Share of Antidiabetic SGLT-2 Inhibitor by Type (2016-2021)
Figure 48. Sales Market Share of Antidiabetic SGLT-2 Inhibitor by Application (2016-2021)
Figure 49. Sales Market Share of Antidiabetic SGLT-2 Inhibitor by Application in 2020
Figure 50. Revenue Share of Antidiabetic SGLT-2 Inhibitor by Application (2016-2021)
Figure 51. Revenue Share of Antidiabetic SGLT-2 Inhibitor by Application in 2020
Figure 52. Manufacturing Cost Structure of Antidiabetic SGLT-2 Inhibitor
Figure 53. Manufacturing Process Analysis of Antidiabetic SGLT-2 Inhibitor
Figure 54. Antidiabetic SGLT-2 Inhibitor Industrial Chain Analysis
Figure 55. Channels of Distribution
Figure 56. Distributors Profiles
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Metformin Hydrochloride Market Research Report 2024

Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 104

Metformin hydrochloride is The raw material of finished product metformin hydrochloride drugs. That is The API metformin hydrochloride. Metformin Hydrochloride finished product is an oral antihyperglycemic drug used in The management of type 2-diabetes. Metformin hydrochloride (N, N-dimethylimidodicarbonimidic diamide hydrochloride) is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Metformin hydrochloride is a white to off-white crystall......

Global Antidiabetic Sulphonylureas Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 112

Market Overview of Global Antidiabetic Sulphonylureas market: According to our latest research, the global Antidiabetic Sulphonylureas market looks promising in the next 5 years. As of 2022, the global Antidiabetic Sulphonylureas market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of t......

Global Insulin Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101

According to our LPI (LP Information) latest study, the global Insulin market size was valued at US$ million in 2023. With growing demand in downstream market, the Insulin is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Insulin market. Insulin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization......

Global Insulin API Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 116

According to our LPI (LP Information) latest study, the global Insulin API market size was valued at US$ 1707.6 million in 2023. With growing demand in downstream market, the Insulin API is forecast to a readjusted size of US$ 2101.4 million by 2030 with a CAGR of 3.0% during review period. The research report highlights the growth potential of the global Insulin API market. Insulin API are expected to show stable growth in the future market. However, product differentiation, reducing co......

Global Glucagon Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101

According to our LPI (LP Information) latest study, the global Glucagon market size was valued at US$ 543.9 million in 2023. With growing demand in downstream market, the Glucagon is forecast to a readjusted size of US$ 835.7 million by 2030 with a CAGR of 6.3% during review period. The research report highlights the growth potential of the global Glucagon market. Glucagon are expected to show stable growth in the future market. However, product differentiation, reducing costs, and suppl......

Global Acarbose Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95

According to our LPI (LP Information) latest study, the global Acarbose market size was valued at US$ 135.8 million in 2023. With growing demand in downstream market, the Acarbose is forecast to a readjusted size of US$ 165.9 million by 2030 with a CAGR of 2.9% during review period. The research report highlights the growth potential of the global Acarbose market. Acarbose are expected to show stable growth in the future market. However, product differentiation, reducing costs, and suppl......

Global Insulin Glargine Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 77

According to our LPI (LP Information) latest study, the global Insulin Glargine market size was valued at US$ 6562.1 million in 2023. With growing demand in downstream market, the Insulin Glargine is forecast to a readjusted size of US$ 8722.5 million by 2030 with a CAGR of 4.1% during review period. The research report highlights the growth potential of the global Insulin Glargine market. Insulin Glargine are expected to show stable growth in the future market. However, product differen......

Global Liraglutide Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 103

According to our LPI (LP Information) latest study, the global Liraglutide market size was valued at US$ million in 2023. With growing demand in downstream market, the Liraglutide is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Liraglutide market. Liraglutide are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply ch......

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96

According to our LPI (LP Information) latest study, the global Glucagon Like Peptide-1 (GLP-1) Agonists market size was valued at US$ 8624.4 million in 2023. With growing demand in downstream market, the Glucagon Like Peptide-1 (GLP-1) Agonists is forecast to a readjusted size of US$ 21310 million by 2030 with a CAGR of 13.8% during review period. The research report highlights the growth potential of the global Glucagon Like Peptide-1 (GLP-1) Agonists market. Glucagon Like Peptide-1 (GL......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs